Biotech firm Moderna has scored regulatory approval for its COVID-19 vaccines to be inoculated to adolescents in Switzerland, Swissmedic announced.
- Swissmedic approved Moderna Switzerland GmbH’s application to extend the temporary authorization for the Spikevax COVID-19 vaccines in adolescents aged 12 to 17.
- The Swissmedic studied 3,732 children aged 12 to 17 and found that a similar dosage for adults produced a similar immune response for COVID-19 to adults aged 18 to 25. Side effects for the age groups were also similar.
- Clinical trial results showed that the vaccine showed the efficacy of about 93% against symptomatic disease in the age group two weeks after the second dose. Side effects usually lasted between one and three days and may be more pronounced after the second dose.
Results showed that the vaccine must be administered in two doses given four weeks apart for adults. MRNA is down 0.36% premarket.